Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group,
fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK
Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing
wearing off symptoms and levodopa-induced dyskinesia.